Back

Targeted anticoagulant reversal, unintended consequences: lessons from andexanet alfa

European Heart Journal - Cardiovascular Pharmacotherapy

13 March 2026
Organised by: Logo
Read full article
ESC Journals

Contributors

Jerrold H Levy
Jerrold H Levy

Author

Duke University Health System Durham , United States of America

Joseph R Shaw
Joseph R Shaw

Author

You may be interested in
thumbnail
Congress Presentation
Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).
26 August 2022
thumbnail
Congress Presentation
Clinical outcomes after reversal of dabigatran in daily practice: real-world use of idarucizumab 2015-2019
28 August 2020
thumbnail
Congress Presentation
Factor XI inhibition uncoupled: mechanistic insights and rationale
30 August 2024
thumbnail
Congress Presentation
Anticoagulation while on MCS: theory and practice
26 March 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources